Researchers at the University of Alabama at Birmingham, led by Donald Buchsbaum, PhD, received a $2.2 million grant from the NIH this year to study pancreatic cancer. According to the University of Alabama website, Dr. Buchsbaum is quoted as saying of his research goals: "My interests are focused on the use of monoclonal antibodies that bind to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors for cancer therapy in combination with chemotherapy agents and radiation.” Dr. Buchsbaum and his research team began receiving funding for their studies of pancreatic cancer six years ago, though funding was limited at that time. The NIH RePORTER sheds light on the project that has received $2.2 million from the NIH this year in the proposal’s abstract:
“This proposal has 4 major projects: Project 1 is utilizing proteomic techniques in transgenic animal models to identify biomarkers that are predictive of early stage pancreatic cancer; Project 2 is a continuation project which is examining multiple methods to enhance the therapeutic efficacy of anti-DR5 monoclonal antibodies in pancreatic cancer animal models and patients; Project 3 is utilizing genomic and genetic data obtained from human pancreatic cancer (PCa) samples and observations from mouse models of PCa to understand the genetic events that drive metastasis and treatment resistance in this disease. These studies will lead to a phase I clinical trial; Project 4 is engineering novel conditionally replicative adenoviral vectors that target pancreatic cancer stem cell-like tumor cells for the treatment of metastatic pancreatic cancer. The four important and effective Cores are: 1) Administration; 2) Tissue Resource and Molecular Pathology; 3) Biostatistics; and 4) Clinical Management and Trials (Advocacy Sub-Core).”
Birmingham BioResearch Product Faire™ Event 2012
In addition to this latest NIH grant, the University of Alabama receives a great deal more NIH and NSF research funding. Lab suppliers marketing life science products and lab products may be interested to know that in 2012, the NIH awarded the University of Alabama at Birmingham $207.4 million. For a full list of schools receiving funding from the NIH at the University of Alabama at Birmingham, please visit the NIH website. What’s more, the NSF awarded the University of Alabama at Birmingham $6.1 million in 2012. For more NSF funding statistics on the University of Alabama, please visit the NSF website.
If you are a lab supplier interested in marketing your life science products and lab products at Alabama life science marketing events, Biotechnology Calendar, Inc. invites you to attend our annual Birmingham BioResearch Product Faire™ Event on November 14th, 2013. Last year, the Birmingham BioResearch Product Faire™ Event attracted 336 attendees. Of the attendees, 64 were purchasing agents, professors and post docs, and 62 were lab managers. The attendees came from 33 different research buildings and 45 departments across campus.
Biotechnology Calendar, Inc. is a full-service science research marketing and events-planning company that organizes life science marketing events at top research universities across the country. If you’re interested in marketing your life science products and lab products at life science marketing events closer to home, we encourage you to view our 2013 calendar of events. For more information on the Birmingham BioResearch Product Faire™ Event, or to view more detailed funding statistics on the University of Alabama at Birmingham, click on the button below.